Information  X 
Enter a valid email address

Tiziana Life Sci PLC (TILS)

  Print      Mail a friend

Thursday 19 April, 2018

Tiziana Life Sci PLC

Subscription

RNS Number : 3791L
Tiziana Life Sciences PLC
19 April 2018
 

Tiziana Life Sciences plc

("Tiziana" or the "Company")

 

Subscription raising £825,000

London, April 19, 2018 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that it has raised £825,000 in cash by the issue of 1,031,250 new ordinary shares at a price of 80p per share. In addition, the Company has issued 51,563 new ordinary shares credited as fully paid and 51,563 warrants exercisable at a price of 80p per share to intermediaries in lieu of commissions on the funds raised.

The Company has undertaken a number of smaller fund raises over past year to provide it with its working capital requirement.  As the Company is at pre-revenue stage and engaged in research and development, it continues to be reliant on raising further funds in the equity markets to provide it with its on-going working capital requirement.

Application has been made to the London Stock Exchange to admit the 1,082,813 new ordinary shares to trading on AIM.  Admission of the new ordinary shares is expected to occur on or around 23 April 2018.  The new ordinary shares will rank pari passu with the existing ordinary shares. Following the issue of shares detailed above the so enlarged issued share capital of the Company will comprise 126,904,285 ordinary shares of 3p each.

The Company has granted options over a total of 10,717,403 ordinary shares of which 5,085,833 are vested at exercise prices between 15p and £1.25p per share and 5,631,570 remain subject to vesting conditions (at potential exercise prices ranging from 15p to £1.925 per share). In addition warrants to subscribe for a total of 5,060,809 ordinary shares at exercise prices between 50p and £2.50 are outstanding (including the warrants referred to above).

Therefore the fully diluted issued share capital of the Company is 142,682,497 ordinary shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

In conformity with DTR 5.6.1 the Company notifies that as at the date of this announcement, it has a single class of shares in issue being ordinary shares of 3 pence each ("Ordinary Shares") and that following the issue of the 1,082,813 Ordinary Shares referred to above, the total number of Ordinary Shares in issue will be 126,904,285.  There are no Ordinary Shares held in Treasury.  Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

This figure of 126,904,285 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.  The content of this announcement has been reviewed and approved for publication by Tiziano Lazzaretti, Chief Financial Officer of the Company.

 

 

Contacts

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

 

+44 (0) 20 7493 2853

Cairn Financial Advisers LLP
(Nominated adviser)

Liam Murray / Jo Turner

 

+44 (0)20 7213 0880

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKFDPPBKDBQD

a d v e r t i s e m e n t